Suppr超能文献

I期与II - III期多发性骨髓瘤中骨髓血管生成及其与其他疾病特征的相关性

Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.

作者信息

Niemöller Kathrin, Jakob Christian, Heider Ulrike, Zavrski Ivana, Eucker Jan, Kaufmann Olaf, Possinger Kurt, Sezer Orhan

机构信息

Department of Oncology and Hematology, Universitätsklinikum Charité, Humboldt-Universität zu Berlin, 10098, Berlin, Germany.

出版信息

J Cancer Res Clin Oncol. 2003 Apr;129(4):234-8. doi: 10.1007/s00432-003-0432-z. Epub 2003 Apr 17.

Abstract

PURPOSE

We studied bone marrow angiogenesis in different stages of multiple myeloma according to the Durie and Salmon classification and its correlations with other disease characteristics.

METHODS

Sixty-five immunohistochemical CD34-stained, paraffin-embedded bone marrow biopsies of multiple myeloma patients and 12 controls were studied. The mean number of microvessels per area in each sample was determined as the microvessel density (MVD). In addition, plasma cell infiltration of the bone marrow, serum beta2-microglobulin, immunoglobulin levels, C-reactive protein, and serum calcium concentration were measured in 22 patients with stage I multiple myeloma and in 43 patients in stage II-III.

RESULTS

In myeloma patients, the bone marrow MVD was significantly higher than in controls (P<0.001). In 43 patients with stage II-III multiple myeloma, MVD was significantly higher than in 22 patients with stage I (median MVD 46 and 21 vessels/mm(2), respectively, P=0.005). Additionally, in stage II-III the bone marrow MVD correlated positively with the bone marrow plasma cell infiltration (r=0.55, P<0.001) and the serum beta2-microglobulin level (r=0.53, P<0.001), while in stage I patients no correlation could be found.

CONCLUSIONS

Angiogenesis is significantly increased in stage II-III myeloma in comparison to stage I. In stages II-III, bone marrow angiogenesis is correlated with plasma cell infiltration and serum beta2-microglobulin levels.

摘要

目的

我们根据杜里和萨尔蒙分类法研究了多发性骨髓瘤不同阶段的骨髓血管生成情况及其与其他疾病特征的相关性。

方法

研究了65例经免疫组织化学CD34染色的多发性骨髓瘤患者石蜡包埋骨髓活检标本以及12例对照标本。测定每个样本每单位面积微血管的平均数作为微血管密度(MVD)。此外,对22例I期多发性骨髓瘤患者和43例II - III期患者测量了骨髓浆细胞浸润、血清β2 - 微球蛋白、免疫球蛋白水平、C反应蛋白和血清钙浓度。

结果

骨髓瘤患者的骨髓MVD显著高于对照组(P < 0.001)。在43例II - III期多发性骨髓瘤患者中,MVD显著高于22例I期患者(MVD中位数分别为46和21条血管/mm²,P = 0.005)。此外,在II - III期,骨髓MVD与骨髓浆细胞浸润呈正相关(r = 0.55,P < 0.001)以及与血清β2 - 微球蛋白水平呈正相关(r = 0.53,P < 0.001),而在I期患者中未发现相关性。

结论

与I期相比,II - III期骨髓瘤的血管生成显著增加。在II - III期,骨髓血管生成与浆细胞浸润和血清β2 - 微球蛋白水平相关。

相似文献

1
Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.
J Cancer Res Clin Oncol. 2003 Apr;129(4):234-8. doi: 10.1007/s00432-003-0432-z. Epub 2003 Apr 17.
2
Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.
J Cancer Res Clin Oncol. 2015 Aug;141(8):1503-9. doi: 10.1007/s00432-015-1952-z. Epub 2015 Mar 13.
5
¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Clin Exp Med. 2015 Feb;15(1):1-18. doi: 10.1007/s10238-014-0308-3. Epub 2014 Sep 14.
7
Prognostic impact of angiopoietin-2 in multiple myeloma.
J Cancer Res Clin Oncol. 2014 Oct;140(10):1801-5. doi: 10.1007/s00432-014-1731-2. Epub 2014 Jun 8.
8
Early versus deferred treatment for early stage multiple myeloma.
Cochrane Database Syst Rev. 2003;2003(1):CD004023. doi: 10.1002/14651858.CD004023.
9
Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma.
J Cancer Res Clin Oncol. 2019 Jun;145(6):1601-1611. doi: 10.1007/s00432-019-02896-1. Epub 2019 Mar 19.
10
Exploring the prognostic value of combined assessment of bone marrow plasma cell morphology, Vitamin D, and interleukin-6 in multiple myeloma.
Front Med (Lausanne). 2025 Jun 18;12:1593130. doi: 10.3389/fmed.2025.1593130. eCollection 2025.

引用本文的文献

1
Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
2
Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
Ann Lab Med. 2015 Nov;35(6):563-9. doi: 10.3343/alm.2015.35.6.563.
5
Bcl-xl expression in multiple myeloma.
Med Oncol. 2005;22(2):183-90. doi: 10.1385/MO:22:2:183.
6
Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.
J Cancer Res Clin Oncol. 2004 Aug;130(8):469-74. doi: 10.1007/s00432-004-0578-3. Epub 2004 Jun 15.
7
Correlation of P-glycoprotein expression with poor vascularization in human gallbladder carcinomas.
World J Gastroenterol. 2003 Dec;9(12):2817-20. doi: 10.3748/wjg.v9.i12.2817.

本文引用的文献

2
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.
J Natl Cancer Inst. 2002 Jun 19;94(12):883-93. doi: 10.1093/jnci/94.12.883.
4
Angiogenesis in multiple myeloma.
Leuk Res. 2002 Jul;26(7):701-2. doi: 10.1016/s0145-2126(01)00168-0.
6
Expression of angiogenic factors and tumor progression in human neuroblastoma.
J Cancer Res Clin Oncol. 2001 Dec;127(12):739-43. doi: 10.1007/s004320100293.
7
Therapeutic application of thalidomide in multiple myeloma.
Semin Oncol. 2001 Dec;28(6):583-7. doi: 10.1016/s0093-7754(01)90028-4.
8
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.
Blood. 2001 Dec 15;98(13):3846-8. doi: 10.1182/blood.v98.13.3846.
10
Cyclooxygenase-2: a novel target for cancer chemotherapy?
J Cancer Res Clin Oncol. 2001 Jul;127(7):411-7. doi: 10.1007/s004320000225.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验